The robust revenue growth trend continues at Gerresheimer AG, one of the world's leading partners of the pharma and healthcare industry. "Our revenues continued to develop very positively in the second quarter of 2012. This growth is being achieved in emerging markets with standard glass and plastic pharmaceutical packaging products and in established markets with sophisticated products for drug dosage and administration. "Since we expect the growth trend to continue in the second six months of the year we increase our revenue forecast for 2012 again and are planning substantial investments in these growth markets," said Uwe Röhrhoff, CEO of Gerresheimer AG. Group revenues rise 10.3% to EUR 314.0M in Q2 2012 - Adjusted EBITDA increases by 4.3% to EUR 58.6M - Net income rises to EUR 17.4M and EPS to EUR 0.51 - Revenue forecast raised from 7-8% to 9-10% at constant exchange rates - Expected investment volume rises from around EUR 100M to around EUR 120M.
